Latest Breaking News On - Results from - Page 1 : comparemela.com

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic profile based on the relevant PK modeling data Additional.

United statesLas vegasChristoph correllEric hughesInvega sustennaZucker school of medicineTeva neuroscience incTeva pharmaceuticalsTeva pharmaceutical industries ltdTeva at psych congress elevateMental health services administrationPsych congress elevateNational pregnancy registry for atypical antipsychoticsTeva pharmaceutical industriesExecutive vice presidentChief medical officer

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive.

United statesUniversity of chicagoCiltacabtagene autoleucelSusan bobulskyLisocabtagene maraleucelObecabtagene autoleucelBrexucabtagene autoleucel brexuKarina calzadillaErica jonesIdecabtagene vicleucel ideVendexv pomalidomideExchange commissionAmerican society of clinical oncologyAcalabrutinib and obinutuzumabAdaptive biotechnologies corporation nasdaqEuropean hematology association

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs standard-of-care TKIs in adults with newly diagnosed CML

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs standard-of-care TKIs in adults with newly diagnosed CML
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalJonathan grahamMichael meoSloan simpsonMarlena abdinoorGerald clementsNicole zinsli sommSatoshi sugimotoIsabella zinckParag mahantiShreeram aradhyeTim hughesImke kappesSteering committeeNovartis europharm

Novartis Pharma AG: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs standard-of-care TKIs in adults with newly diagnosed CML

Novartis Pharma AG: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs standard-of-care TKIs in adults with newly diagnosed CML
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalSloan simpsonGerald clementsTim hughesMarlena abdinoorNicole zinsli sommParag mahantiImke kappesShreeram aradhyeMichael meoSatoshi sugimotoIsabella zinckJonathan grahamEuropean hematology associationDmax foundation

Adaptive Biotechnologies Announces Data Supporting the

Adaptive Biotechnologies Announces Data Supporting the
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

University of chicagoUnited statesIdecabtagene vicleucel ideErica jonesSusan bobulskyVendexv pomalidomideObecabtagene autoleucelBrexucabtagene autoleucel brexuLisocabtagene maraleucelKarina calzadillaCiltacabtagene autoleucelAcalabrutinib and obinutuzumabCancer center clinica universidad de navarraExchange commissionAmerican society of clinical oncologyEuropean hematology association